CTOs on the Move

KSQ Therapeutics

www.ksqtx.com

 
KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ksqtx.com
  • 4 Maguire Road
    Lexington, MA USA 02421
  • Phone: 617.674.9150

Executives

Name Title Contact Details
Thomas Leitch
Chief Technology Officer Profile

Funding

KSQ Therapeutics raised $76M on 10/02/2017
KSQ Therapeutics raised $80M on 09/28/2018

Similar Companies

Lantheus

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.

Nussentials

Nussentials is a Eufaula, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fisher Scientific unit of ThermoFisherScientific

Fisher Scientific Company L.L.C. is the principal U.S. operating subsidiary of Fisher Scientific International Inc. (NYSE: FSH), the world leader in serving science.

San Luis Valley Regional Medical Center

San Luis Valley Regional Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Alamosa, CO. To find more information about San Luis Valley Regional Medical Center, please visit www.slvrmc.org